This large, single-center study — conducted over seven years (2016-2023) — reviewed outcomes in 175 septic shock patients treated with CytoSorb. It represents the most extensive dataset from a single center to date, offering a real-world look at how timing and intensity of treatment can influence survival.

A newly published meta-analysis by Steindl et al. in J Clin Med (2025;14:2285) presents compelling evidence for the effectiveness of CytoSorb hemoadsorption therapy in patients with septic shock — a patient group not yet targeted specifically in prior meta-analyses.

The Role of Extracorporeal Blood Purification Techniques in the Treatment of Septic Shock: a review based on the recent position paper by Bottari et al (1), with particular consideration of CytoSorb hemoadsorption therapy

Prof Dr Daniel Wendt on the results of the second interim STAR Registry analysis: “Hemoadsorption appears to be a feasible, safe and potentially effective solution for reducing perioperative bleeding in patients on oral anticoagulants”

The CytoSorb Literature Database has just surpassed 1,000 entries – One thousand peer reviewed publications, poster presentations from national and international conferences and case reports from many different hospitals worldwide. As such, CytoSorb stands as the most researched and published hemoadsorption therapy of its kind.

Prof Dr Daniel Wendt on: Intraoperative hemoadsorption for antithrombotic drug removal during cardiac surgery: Initial report of the International Safe and Timely Antithrombotic Removal (STAR) Registry.